PT3613439T - Recetor de antigénio quimérico e métodos de utilização do mesmo - Google Patents

Recetor de antigénio quimérico e métodos de utilização do mesmo

Info

Publication number
PT3613439T
PT3613439T PT191883982T PT19188398T PT3613439T PT 3613439 T PT3613439 T PT 3613439T PT 191883982 T PT191883982 T PT 191883982T PT 19188398 T PT19188398 T PT 19188398T PT 3613439 T PT3613439 T PT 3613439T
Authority
PT
Portugal
Prior art keywords
methods
chimeric antigen
receiver
antigen receiver
chimeric
Prior art date
Application number
PT191883982T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PT3613439T publication Critical patent/PT3613439T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
PT191883982T 2013-02-15 2014-02-14 Recetor de antigénio quimérico e métodos de utilização do mesmo PT3613439T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361765585P 2013-02-15 2013-02-15

Publications (1)

Publication Number Publication Date
PT3613439T true PT3613439T (pt) 2021-05-12

Family

ID=51354582

Family Applications (3)

Application Number Title Priority Date Filing Date
PT191883982T PT3613439T (pt) 2013-02-15 2014-02-14 Recetor de antigénio quimérico e métodos de utilização do mesmo
PT171872930T PT3300745T (pt) 2013-02-15 2014-02-14 Recetor de antigénio quimérico e métodos de utilização do mesmo
PT147512271T PT2956175T (pt) 2013-02-15 2014-02-14 Recetor de antigénio quimérico e métodos de utilização do mesmo

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT171872930T PT3300745T (pt) 2013-02-15 2014-02-14 Recetor de antigénio quimérico e métodos de utilização do mesmo
PT147512271T PT2956175T (pt) 2013-02-15 2014-02-14 Recetor de antigénio quimérico e métodos de utilização do mesmo

Country Status (20)

Country Link
US (10) US20150368342A1 (enExample)
EP (5) EP4303232A3 (enExample)
JP (5) JP6450690B2 (enExample)
KR (5) KR102813881B1 (enExample)
CN (2) CN105142677B (enExample)
AU (5) AU2014216130B2 (enExample)
CA (1) CA2901115A1 (enExample)
CY (1) CY1122386T1 (enExample)
DK (2) DK3300745T3 (enExample)
ES (3) ES2868247T3 (enExample)
HR (1) HRP20192123T1 (enExample)
HU (2) HUE036250T2 (enExample)
IL (3) IL272279B2 (enExample)
LT (2) LT2956175T (enExample)
MX (2) MX369545B (enExample)
NO (1) NO2929995T3 (enExample)
PL (3) PL2956175T3 (enExample)
PT (3) PT3613439T (enExample)
SI (2) SI3300745T1 (enExample)
WO (1) WO2014127261A1 (enExample)

Families Citing this family (338)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
EP3653212B1 (en) 2012-12-20 2023-04-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
PT3613439T (pt) 2013-02-15 2021-05-12 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
AU2014236726A1 (en) 2013-03-14 2015-09-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
ES3058841T3 (en) 2013-03-15 2026-03-13 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP6543626B2 (ja) 2013-07-29 2019-07-10 ブルーバード バイオ， インコーポレイテッド 多部分シグナル伝達タンパク質およびその使用
WO2015042707A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
KR102225489B1 (ko) 2013-12-17 2021-03-10 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
EP4420663A3 (en) * 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
AU2015206040B2 (en) * 2014-01-14 2018-11-01 Cellectis Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
EP3119425B1 (en) * 2014-03-15 2020-09-23 Novartis AG Regulatable chimeric antigen receptor
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
SI3888674T1 (sl) 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
ES2995052T3 (en) 2014-04-23 2025-02-05 Juno Therapeutics Inc Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
CN107106665A (zh) * 2014-06-06 2017-08-29 纪念斯隆-凯特琳癌症中心 靶向间皮素的嵌合抗原受体及其用途
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
ES3034398T3 (en) * 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
WO2016036746A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
EP3699188A1 (en) 2014-09-04 2020-08-26 Cellectis 5t4 (tpbg) specific chimeric antigen receptors for cancer immunotherapy
JP6839074B2 (ja) * 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
JP2017532325A (ja) * 2014-10-03 2017-11-02 イエール ユニバーシティ 抗癌療法のための自然免疫系の改変
MX2017004603A (es) * 2014-10-07 2017-06-30 Cellectis Metodo para modular actividad de celulas inmunes inducidas por car.
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
EP3025719B1 (en) 2014-11-26 2018-09-26 Miltenyi Biotec GmbH Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
WO2016089916A1 (en) * 2014-12-02 2016-06-09 Roger Williams Hospital Methods and compositons for treating cancer
PT3227339T (pt) 2014-12-05 2022-01-14 Eureka Therapeutics Inc Recetores de antigénio quiméricos que têm como alvo o recetor 4 acoplado a proteína g e utilizações dos mesmos
KR20230159637A (ko) 2014-12-05 2023-11-21 메모리얼 슬로안 케터링 캔서 센터 G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
EP3608408A1 (en) * 2014-12-15 2020-02-12 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
US20190054117A1 (en) * 2014-12-19 2019-02-21 Novartis Ag Dimerization switches and uses thereof
CN107995926B (zh) 2014-12-19 2021-07-06 苏黎世联邦理工学院 嵌合抗原受体和使用方法
EP3237436B1 (en) 2014-12-24 2019-05-01 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of molecules
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
KR102632082B1 (ko) 2015-02-27 2024-02-02 아이셀 진 테라퓨틱스 엘엘씨 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도
US10195272B2 (en) 2015-03-02 2019-02-05 The Nemours Foundation Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
CA2981304C (en) * 2015-04-02 2024-01-02 Memorial Sloan Kettering Cancer Center Tnfrsf14/hvem proteins and methods of use thereof
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
EP3283113A4 (en) * 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
AU2016263198C1 (en) 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
MX2017014822A (es) 2015-05-18 2018-04-30 Tcr2 Therapeutics Inc Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
JP6961497B2 (ja) 2015-06-25 2021-11-05 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
EP3575403A1 (en) 2015-08-05 2019-12-04 Yoo Young Pharm Co., Ltd. Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
CA2994969A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US11667691B2 (en) * 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CA2995632C (en) 2015-08-24 2023-02-07 Cellectis Chimeric antigen receptors with integrated controllable functions
AU2016315941B2 (en) 2015-09-01 2022-09-08 The Regents Of The University Of California Modular polypeptide libraries and methods of making and using same
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
KR20180053744A (ko) 2015-09-23 2018-05-23 사이토이뮨 테라퓨틱스 엘엘씨 면역 요법을 위한 flt3 유도된 car 세포
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
US20210206826A1 (en) * 2015-11-19 2021-07-08 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
JP7621053B2 (ja) * 2015-11-23 2025-01-29 トラスティーズ オブ ボストン ユニバーシティ キメラ抗原受容体に関する方法および組成物
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
EP3184548A1 (en) 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
AU2016380262B2 (en) 2015-12-28 2023-02-09 Novartis Ag Methods of making chimeric antigen receptor -expressing cells
BR112018013914A2 (pt) * 2016-01-08 2018-12-11 Univ California polipeptídeos heterodiméricos condicionalmente ativos e métodos de utilização deste
JP7012645B2 (ja) 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
MX2018008344A (es) 2016-01-11 2018-12-06 Univ Leland Stanford Junior Proteinas quimericas y metodos para regular la expresion genica.
CN105567640A (zh) * 2016-01-27 2016-05-11 苏州佰通生物科技有限公司 一种嵌合抗原受体脂肪干细胞及其制备方法
GB201602571D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602563D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
US10871490B2 (en) 2016-02-29 2020-12-22 Multenyi Biotec, gmbH Assay for detection of chimeric antigen receptor T cells
JP7208010B2 (ja) * 2016-03-29 2023-01-18 ユニバーシティ オブ サザン カリフォルニア 癌を標的とするキメラ抗原受容体
CA3018253A1 (en) 2016-03-31 2017-10-05 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
KR102694879B1 (ko) 2016-04-01 2024-08-16 암젠 인크 Flt3에 대한 키메라 수용체 및 이의 사용 방법
WO2017173349A1 (en) 2016-04-01 2017-10-05 Kite Pharma, Inc. Bcma binding molecules and methods of use thereof
UA123276C2 (uk) 2016-04-01 2021-03-10 Кайт Фарма, Інк. Химерний рецептор та спосіб лікування пухлини або злоякісного новоутворення
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN109311963A (zh) 2016-04-14 2019-02-05 蓝鸟生物公司 救助嵌合抗原受体系统
SG11201808831TA (en) 2016-04-15 2018-11-29 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
EP3455261B1 (en) 2016-05-13 2022-08-03 BioAtla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3464375A2 (en) 2016-06-02 2019-04-10 Novartis AG Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
US11384156B2 (en) 2016-07-25 2022-07-12 The Nemours Foundation Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2017307610B2 (en) 2016-08-04 2023-10-05 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
WO2018045034A1 (en) 2016-08-30 2018-03-08 Promab Biotechnologies, Inc. Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain
US20180064758A1 (en) * 2016-09-05 2018-03-08 Ucl Business Plc Chimeric antigen receptor
CN107793483B (zh) * 2016-09-06 2019-08-23 伍志强 嵌合抗原受体及其基因和重组表达载体、carmsln-nkt细胞及其制备方法和应用
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
US10683355B2 (en) 2016-09-16 2020-06-16 Kissei Pharmaceutical Co., Ltd. Genetically-modified cells and method for producing same
ES2811500T3 (es) * 2016-10-04 2021-03-12 Prec Biosciences Inc Dominios coestimuladores para su uso en células genéticamente modificadas
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
ES2916335T3 (es) * 2016-10-20 2022-06-30 Celgene Corp Receptores de antígeno quimérico heterodimerizable basados en cereblon
US12227578B2 (en) 2016-11-11 2025-02-18 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN107058315B (zh) * 2016-12-08 2019-11-08 上海优卡迪生物医药科技有限公司 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
AU2017378153B2 (en) 2016-12-13 2024-03-28 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
WO2018112266A1 (en) 2016-12-14 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
CA3048648A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation T cells expressing a chimeric antigen receptor
CN107573419A (zh) * 2017-01-24 2018-01-12 深圳市体内生物医药科技有限公司 一种增强t细胞抗肿瘤活性的核酸分子
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
EP3580212A4 (en) * 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. REGULATION OF CHEMERIC ANTIGEN RECEPTORS
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
JP7341900B2 (ja) * 2017-03-03 2023-09-11 オブシディアン セラピューティクス， インコーポレイテッド 免疫療法のためのｃｄ１９組成物及び方法
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
AU2018245749A1 (en) 2017-03-27 2019-10-03 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CA3056439A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
JOP20180027A1 (ar) 2017-03-28 2019-01-30 Cell Design Labs Inc بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
WO2018183888A2 (en) 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
EP3606950A1 (en) * 2017-05-12 2020-02-12 Cellectis Protease based switch chimeric antigen receptors for safer cell immunotherapy
JP7132249B2 (ja) * 2017-05-15 2022-09-06 オートラス リミテッド キメラ抗原受容体（ｃａｒ）を含む細胞
CN107141356B (zh) * 2017-06-07 2020-03-13 胜武（北京）生物科技有限公司 一种光诱导二聚体型嵌合抗原受体
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
EP3641768B1 (en) 2017-06-21 2025-12-31 iCell Gene Therapeutics LLC Chimeric Antigen Receptors (CARs), Compositions and Associated Methods
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
CN107446937B (zh) * 2017-09-05 2020-12-25 深圳华云生物技术有限公司 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用
WO2019051001A1 (en) * 2017-09-06 2019-03-14 California Institute Of Technology SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR)
CN109504697A (zh) * 2017-09-15 2019-03-22 上海恒润达生生物科技有限公司 一种靶向人源化mesothelin的嵌合抗原受体的方法和用途
EP3684424A4 (en) * 2017-09-22 2021-09-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. CHIMERA ANTIGEN RECEPTORS WITH IMPROVED NFKB SIGNALING
CN109553686A (zh) * 2017-09-26 2019-04-02 南京安吉生物科技有限公司 一种新型可调控的双嵌合抗原受体t细胞及其构建方法和应用
GB201715918D0 (en) * 2017-09-29 2017-11-15 Tc Biopharm Ltd Modified CAR-T
WO2019067677A1 (en) 2017-09-29 2019-04-04 Cell Design Labs, Inc. METHODS OF MANUFACTURING RECEPTORS OF ANTI-CD307E ANTI-BACTERIAL CHIMERIC ANTIGENS AND USES THEREFOR
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
RU2020116579A (ru) 2017-10-25 2021-11-25 Новартис Аг Способы получения клеток, экспрессирующих химерный антигенный рецептор
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
WO2019099707A1 (en) 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
EP3723787A4 (en) * 2017-12-14 2021-09-01 Bluebird Bio, Inc. DARIC INTERLEUKIN RECEPTORS
US12187776B2 (en) 2017-12-14 2025-01-07 Celyad S.A. Pooling signaling and costimulatory domains in B7H6 chimeric antigen receptor
EP3502130A1 (en) 2017-12-20 2019-06-26 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
KR20200101942A (ko) 2017-12-20 2020-08-28 세인트 안나 킨더크렙스포르슝 리간드 조절 단백질-단백질 상호작용 시스템
IL309585B2 (en) 2017-12-22 2025-03-01 Fate Therapeutics Inc Enhanced immune effector cells and use thereof
US12570958B2 (en) 2017-12-22 2026-03-10 Cell Design Labs, Inc. Single- and multi-chain chimeric antigen receptors
WO2019134950A1 (en) 2018-01-04 2019-07-11 Miltenyi Biotec Gmbh Chimeric antigen receptor specific for bdca2 antigen
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
AU2019209428B2 (en) 2018-01-22 2025-06-26 Endocyte, Inc. Methods of use for CAR T cells
CN108017717B (zh) 2018-01-24 2019-08-16 首都医科大学宣武医院 一种用于体外高效定向扩增的嵌合抗原受体及其应用
CA3090089A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CN118772287A (zh) * 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
SG11202007156QA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
US20210023170A1 (en) * 2018-02-12 2021-01-28 University Of Florida Research Foundation, Incorporated Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a
KR102618231B1 (ko) 2018-02-16 2023-12-28 카이트 파마 인코포레이티드 변형된 만능성 줄기 세포, 및 제조 및 사용 방법
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
TW202000693A (zh) 2018-02-27 2020-01-01 美商葛利史東腫瘤科技公司 利用泛對偶基因（pan-allele）模型之新抗原鑑別
WO2019168923A1 (en) 2018-03-01 2019-09-06 University Of Kansas Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
JP2021514648A (ja) * 2018-03-01 2021-06-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規の標的抗原結合部分のための特異性アッセイ
US11813292B2 (en) * 2018-03-12 2023-11-14 Immunity Bio, Inc. Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)
EP3765491B1 (en) * 2018-03-14 2024-04-03 Medigene Immunotherapies GmbH Inducible t cell receptors and uses thereof
EP3775228A4 (en) 2018-03-29 2022-02-23 Fate Therapeutics, Inc. ENHANCED IMMUNE EFFECTIVE CELLS AND THEIR USE
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
EP3773623A4 (en) * 2018-04-06 2022-01-05 The Regents of The University of California TRANS ANTIGEN TARGETING IN HETEROGENIC CARCINOMA AND METHOD OF USING IT
AU2019249215B2 (en) 2018-04-06 2026-02-19 The Regents Of The University Of California Methods of treating EGFRvIII expressing glioblastomas
UA129466C2 (uk) 2018-04-10 2025-05-07 Емджен Інк. Химерні рецептори до dll3 та способи їх застосування
CN108410908B (zh) * 2018-04-12 2021-08-03 吉林大学 一种利用植物激素ga及小分子物质pac调节细胞通路的方法
WO2019197676A1 (en) * 2018-04-13 2019-10-17 Ludwig Institute For Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
WO2019203600A1 (ko) 2018-04-18 2019-10-24 앱클론(주) 스위치 분자 및 스위처블 키메라 항원 수용체
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US12473342B2 (en) 2018-04-27 2025-11-18 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
CN112041436A (zh) 2018-04-27 2020-12-04 西雅图儿童医院（Dba西雅图儿童研究所） 雷帕霉素抗性细胞
CN108715616A (zh) * 2018-04-27 2018-10-30 上海恒润达生生物科技有限公司 靶向人源化间皮素的嵌合抗原受体方法和用途
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
IL321548A (en) 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
EP3802579A1 (en) 2018-06-01 2021-04-14 The Board of Trustees of the Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
CN110577604A (zh) * 2018-06-07 2019-12-17 亘喜生物科技（上海）有限公司 携带gitr共刺激信号靶向egfr的嵌合抗原受体t细胞
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
CA3102641A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
CN110669138A (zh) * 2018-07-02 2020-01-10 中国药科大学 一种双嵌合抗原受体、t细胞及其构建方法与应用
CA3105658A1 (en) 2018-07-13 2020-01-16 The Regents Of The University Of California Retrotransposon-based delivery vehicle and methods of use thereof
BR112021000914A2 (pt) 2018-07-18 2021-04-13 Amgen Inc. Receptores quiméricos para steap1 e seus métodos de uso
CA3108657A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
AU2019321983B2 (en) 2018-08-13 2025-11-20 Aarhus Universitet Genetically altered LysM receptors with altered agonist specificity and affinity
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3844267B1 (en) 2018-08-31 2025-06-25 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3847191A4 (en) * 2018-09-07 2022-06-08 BioAtla, Inc. CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
JP2022512594A (ja) * 2018-10-05 2022-02-07 ザンクト アンナ キンダークレプスフォルシュング キメラ抗原受容体（ｃａｒ）の群
JP2022504191A (ja) * 2018-10-05 2022-01-13 ザンクト アンナ キンダークレプスフォルシュング キメラ抗原受容体（ｃａｒ）群
EP3632460A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
GB201816839D0 (en) * 2018-10-16 2018-11-28 Glaxosmithkline Ip Dev Ltd Novel control switch
WO2020117526A1 (en) 2018-12-02 2020-06-11 Fate Therapeutics, Inc. IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
EP3891185A2 (en) 2018-12-05 2021-10-13 F. Hoffmann-La Roche AG Diagnostic methods and compositions for cancer immunotherapy
WO2020118305A1 (en) * 2018-12-07 2020-06-11 The Trustees Of Columbia University In The City Of New York Muc4 car-t cells for treating cancer
CN120005921A (zh) 2018-12-12 2025-05-16 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
US12291560B2 (en) 2018-12-14 2025-05-06 Regeneron Pharmaceuticals, Inc. Dimerizing agent regulated immunoreceptor complexes
CN113366479A (zh) 2018-12-14 2021-09-07 蓝鸟生物公司 二聚化剂调节的免疫受体复合物
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020141106A1 (en) 2019-01-03 2020-07-09 Kemijski Institut Engineered externally regulated artificial transcription regulatory system based on engineered nfat
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020152197A1 (en) 2019-01-23 2020-07-30 Miltenyi Biotec B.V. & Co. KG A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
MX2021010441A (es) 2019-03-01 2021-09-21 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020191079A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
WO2020201527A1 (en) 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN114007654A (zh) 2019-04-17 2022-02-01 阿迪根有限公司 用于分子的细胞内递送的肽和纳米颗粒
TWI865517B (zh) 2019-04-26 2024-12-11 美商艾洛基因醫療公司 抗利妥昔單抗嵌合抗原受體及其用途
WO2020219812A1 (en) 2019-04-26 2020-10-29 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
AU2020265749A1 (en) 2019-05-01 2022-01-06 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods
SG11202111360YA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
BR112021020999A2 (pt) 2019-05-04 2021-12-14 Inhibrx Inc Polipeptídeos de ligação à clec12a e usos dos mesmos
US12570743B2 (en) * 2019-05-07 2026-03-10 Gracell Bioscience (Shanghai) Co., Ltd. BCMA-targeting engineered immune cell and use thereof
CN113784732B (zh) 2019-05-07 2024-03-22 亘喜生物科技（上海）有限公司 靶向bcma的工程化免疫细胞及其用途
EP3966249A4 (en) 2019-05-08 2023-05-10 2seventy bio, Inc. IMMUNOTHERAPIES TARGETED AGAINST CLL-1
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
US20220220504A1 (en) 2019-05-28 2022-07-14 Miltenyi Biotec B.V. & Co. KG Method for Generation of Genetically Modified T Cells
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US12109235B2 (en) 2019-06-21 2024-10-08 Kite Pharma, Inc. TGF-beta receptors and methods of use
JP2022541320A (ja) * 2019-07-24 2022-09-22 エウレカ セラピューティクス インコーポレイテッド キメラ抗原受容体ｔ細胞及びその使用
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
US20220315894A1 (en) 2019-09-11 2022-10-06 Miltenyi Biotec B.V. & Co. KG Method for Transduction of T Cells in the Presence of Malignant Cells
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
WO2021068068A1 (en) * 2019-10-08 2021-04-15 Provincial Health Services Authority Chimeric cytokine receptors
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
WO2021113116A1 (en) * 2019-12-03 2021-06-10 University Of Massachusetts Compositions and methods for optogenetic immunotherapy
CN115335399A (zh) 2019-12-06 2022-11-11 朱诺治疗学股份有限公司 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
CN113087805A (zh) * 2019-12-31 2021-07-09 华东师范大学 一种共表达免疫调节分子的嵌合抗原受体t细胞的制备及其应用
US20230028399A1 (en) * 2020-01-13 2023-01-26 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
CN115397974A (zh) 2020-01-23 2022-11-25 儿童医疗中心有限公司 由人类多能干细胞进行无基质t细胞分化
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
EP4100428A4 (en) 2020-02-04 2024-03-06 Seattle Children's Hospital (DBA Seattle Children's Research Institute) CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS
CN115066249A (zh) 2020-02-04 2022-09-16 美天施生物科技有限两合公司 表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞
CN115427451B (zh) * 2020-02-14 2026-02-17 北京永泰瑞科生物科技有限公司 过表达从外部导入的细胞信号调节因子的免疫细胞及其用途
EP4104187A1 (en) 2020-02-14 2022-12-21 Novartis AG Method of predicting response to chimeric antigen receptor therapy
KR20220146530A (ko) 2020-02-27 2022-11-01 노파르티스 아게 키메라 항원 수용체-발현 세포의 제조 방법
BR112022016633A2 (pt) 2020-02-27 2022-12-13 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
CN115485289A (zh) * 2020-03-11 2022-12-16 宾夕法尼亚大学董事会 使用工程化的病毒颗粒进行基因递送的方法和组合物
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2021212069A1 (en) 2020-04-17 2021-10-21 City Of Hope Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies
JP7645500B2 (ja) * 2020-05-07 2025-03-14 ブリスター イムノテック リミテッド 改善されたｔ細胞受容体共刺激分子キメラ
EP3916388A1 (en) 2020-05-27 2021-12-01 Miltenyi Biotec B.V. & Co. KG Reagents for detection of chimeric antigen receptor cells
EP3915578A1 (en) 2020-05-28 2021-12-01 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising c2-set ig-like domains
AU2021286655A1 (en) 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
CA3182852A1 (en) 2020-06-19 2021-12-23 Fate Therapeutics, Inc. Combining ipsc-derived effector cell types for immunotherapy use
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
EP4100028A4 (en) * 2020-08-20 2023-07-26 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
EP3964585A1 (en) 2020-09-03 2022-03-09 Miltenyi Biotec B.V. & Co. KG Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets
KR20230061486A (ko) 2020-09-04 2023-05-08 밀테니 비오텍 비.브이. & 씨오. 케이지 면역 세포 내 어댑터의 유도성 발현을 위한 시스템
IL302400A (en) 2020-11-04 2023-06-01 Genentech Inc Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
CA3196191A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2022096664A1 (en) 2020-11-09 2022-05-12 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
MX2023005609A (es) 2020-11-13 2023-05-29 Novartis Ag Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
IL302744A (en) 2020-11-24 2023-07-01 Lyell Immunopharma Inc Methods for production, total preparations and methods of using regenerated T cells
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
US20250268938A1 (en) * 2021-01-29 2025-08-28 Outpace Bio, Inc. Small molecule-regulated cell signaling expression system
US20240115608A1 (en) * 2021-02-10 2024-04-11 The Regents Of The University Of California Immune receptors with synthetic co-stimulatory domains
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
GB202104030D0 (en) * 2021-03-23 2021-05-05 Autolus Ltd Signalling system
WO2022212858A2 (en) * 2021-04-01 2022-10-06 A2 Biotherapeutics, Inc. Polypeptides targeting hla-a*11 and methods of use thereof
WO2022241235A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
AU2022291365B2 (en) 2021-06-08 2026-03-12 Kite Pharma, Inc. Gpc3 binding molecules
GB202108366D0 (en) 2021-06-11 2021-07-28 Quell Therapeutics Ltd Multichain chimeric antigen receptor
US20230060292A1 (en) 2021-07-26 2023-03-02 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
EP4388017A4 (en) 2021-08-20 2026-03-04 Christopher E Rudd COMPOSITIONS AND PROCESSES FOR ANTIVIRAL CHIMERIC ANTIGENIC RECEPTOR
WO2023044304A1 (en) * 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
EP4413031A1 (en) 2021-10-06 2024-08-14 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
KR20240099259A (ko) 2021-10-14 2024-06-28 아스널 바이오사이언시스, 인크. 공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포
WO2023062113A1 (en) 2021-10-15 2023-04-20 Miltenyi Biotec B.V. & Co. KG Method for the generation of genetically modified nk cells
WO2023130462A1 (zh) * 2022-01-10 2023-07-13 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN114736306B (zh) * 2022-03-01 2024-04-19 中国科学院深圳先进技术研究院 一种受化学调控的蛋白酶工具及其配套底物
US20250255959A1 (en) 2022-04-01 2025-08-14 Miltenyi Biotec B.V. & Co. KG A system for drug-inducible expression of a polynucleotide
CN119256075A (zh) 2022-04-08 2025-01-03 菲特治疗公司 具有实体瘤靶向骨架的细胞及其用途
AU2023248529A1 (en) 2022-04-08 2024-10-24 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting
WO2023217796A1 (en) 2022-05-10 2023-11-16 Miltenyi Biotec B.V. & Co. KG Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
WO2023220459A1 (en) * 2022-05-13 2023-11-16 Northwestern University Active loading of cargo entity into lipid bilayer particles using dimerization domains
US20250339464A1 (en) 2022-05-16 2025-11-06 Miltenyi Biotec B.V. & Co. KG Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof
WO2024050325A2 (en) * 2022-09-01 2024-03-07 Sri International Genetically engineered cd4 t-cells for in situ synthesis of proteins
JP2025531220A (ja) 2022-09-15 2025-09-19 ノバルティス アーゲー キメラ抗原受容体療法を使用した自己免疫障害の治療
EP4342488A1 (en) 2022-09-26 2024-03-27 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for folate receptor 1
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
EP4602171A1 (en) 2022-10-15 2025-08-20 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
KR102834479B1 (ko) * 2022-11-04 2025-07-16 한국과학기술연구원 형광공명에너지전이 기반 car 활성 센싱용 바이오센서 및 그의 용도
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024158800A2 (en) * 2023-01-24 2024-08-02 Ginkgo Bioworks, Inc. Immune cell stimulatory sequences
WO2024182539A1 (en) 2023-02-28 2024-09-06 Lyell Immunopharma, Inc. Methods of culturing reprogrammed cells
AU2024244733B2 (en) 2023-03-31 2025-12-11 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
AU2024261890A1 (en) 2023-04-27 2025-10-09 Miltenyi Biotec B.V. & Co. KG Retroviral vector particle pseudotyped with envelope proteins of canine distemper virus
KR20260005358A (ko) 2023-04-27 2026-01-09 밀테니 비오텍 비.브이. & 씨오. 케이지 항-cd3 디스플레이를 갖는 슈도타이핑된 레트로바이러스 벡터 입자
EP4470555A1 (en) 2023-05-31 2024-12-04 Miltenyi Biotec B.V. & Co. KG Anti-tag chimeric antigen receptors with specificity for mutated peptides derived from human fgfr2
EP4471067A1 (en) 2023-06-01 2024-12-04 Miltenyi Biotec B.V. & Co. KG A chemically inducible heterodimerizing system and a method for generation thereof
WO2025008108A1 (en) 2023-07-06 2025-01-09 Miltenyi Biotec B.V. & Co. KG Immune cell expressing chimeric antigen receptor and transgenic t cell receptor
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025078492A1 (en) 2023-10-13 2025-04-17 Miltenyi Biotec B.V. & Co. KG Cd3-targeted nipah-pseudotyped lentiviral vector particles
EP4545963A1 (en) 2023-10-26 2025-04-30 Miltenyi Biotec B.V. & Co. KG Method for selecting antigen recognizing moieties having specificity for a target structure
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025224123A1 (en) 2024-04-25 2025-10-30 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptors specific for fibroblast activation protein
WO2025252325A1 (en) 2024-06-06 2025-12-11 Miltenyi Biotec B.V. & Co. KG A human protein scaffold library based on the pdz3 domain of the tight junction protein zo-1
WO2025252326A1 (en) 2024-06-06 2025-12-11 Miltenyi Biotec B.V. & Co. KG A human protein scaffold library based on the n-terminal domain of human fact complex subunit ssrp1

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2052928A1 (en) * 1990-10-15 1992-04-16 John J. Siekierka Genes encoding the human fk-506 binding protein and a.s. cerevisiae homolog, fkb1 and their expression
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
TW197439B (enExample) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
EP0642586A4 (en) 1992-05-21 1995-11-29 Penn State Res Found CULTURAL -i (TAXUS) FABRIC AS A SOURCE OF TAXOL, RELATED TAXANS AND OTHER NEW ANTI-TUMOR / ANTI-VIRAL SUBSTANCES (01/20/94).
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
FI953812A0 (fi) 1993-02-12 1995-08-11 Univ Leland Stanford Junior Kohdistettujen geenien säädelty transkriptio ja muita biologisia toimintoja
US5310903A (en) 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5525610A (en) 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6133456A (en) 1994-08-18 2000-10-17 Ariad Gene Therapeutics, Inc. Synthetic multimerizing agents
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US6150527A (en) 1994-08-18 2000-11-21 Ariad Pharmaceuticals, Inc. Synthetic multimerizing agents
KR100551104B1 (ko) 1994-12-09 2006-02-09 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
CA2219080A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamycin-based regulation of biological events
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
AU3740997A (en) 1996-08-26 1998-03-19 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
CA2264227A1 (en) 1996-09-27 1998-04-02 Raymond A. Firestone Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
CA2294606A1 (en) 1997-06-20 1998-12-30 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
AU741433B2 (en) 1997-10-08 2001-11-29 Bio Research Corporation Of Yokohama Taxoid derivatives and process for producing the same
AU755784B2 (en) 1998-01-15 2002-12-19 Ariad Pharmaceuticals, Inc. Regulation of biological events using multimeric chimeric proteins
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
GB9925854D0 (en) 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US6916846B2 (en) 2000-05-12 2005-07-12 Merck & Co. Inc. Coumermycin analogs as chemical dimerizers of chimeric proteins
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
CA2425862C (en) 2000-11-07 2013-01-22 City Of Hope Cd19-specific redirected immune cells
GB0105402D0 (en) 2001-03-05 2001-04-18 Inpharmatica Ltd Novel proteins
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
AU2003223244A1 (en) 2002-03-11 2003-09-29 The Johns Hopkins University Molecular switches and methods for making and using the same
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP2557164A1 (en) 2003-02-18 2013-02-13 Kevin M. Slawin Induced activation in dendritic cells
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
US8236925B1 (en) 2005-08-26 2012-08-07 University Of Minnesota Protein nanorings
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2011053825A2 (en) * 2009-10-30 2011-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment or prevention of mitochondrial diseases
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
CN103038343A (zh) * 2010-03-23 2013-04-10 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
EP2558571A4 (en) 2010-04-16 2014-09-24 Immune Disease Inst Inc DELAYED POLYPEPTIDE EXPRESSION FROM MODIFIED SYNTHETIC RNAS AND USES THEREOF
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
JP6121904B2 (ja) 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
FR2968013A1 (fr) * 2010-11-29 2012-06-01 Cis Bio Int Methode de retention conditionnelle d'une proteine d'interet dans le reticulum endoplasmique
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
BR112013018311A2 (pt) * 2011-01-18 2017-03-21 Univ Pennsylvania sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
WO2014055657A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
PT3613439T (pt) 2013-02-15 2021-05-12 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
AU2014236726A1 (en) 2013-03-14 2015-09-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
ES3058841T3 (en) 2013-03-15 2026-03-13 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3057991B8 (en) * 2013-10-15 2019-09-04 The Scripps Research Institute Chimeric antigen receptor t cell switches and uses thereof
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
EP3119425B1 (en) * 2014-03-15 2020-09-23 Novartis AG Regulatable chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
MX2017004603A (es) 2014-10-07 2017-06-30 Cellectis Metodo para modular actividad de celulas inmunes inducidas por car.
US20210206826A1 (en) 2015-11-19 2021-07-08 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
BR112018013914A2 (pt) 2016-01-08 2018-12-11 Univ California polipeptídeos heterodiméricos condicionalmente ativos e métodos de utilização deste

Also Published As

Publication number Publication date
KR102332790B1 (ko) 2021-12-01
JP2016508518A (ja) 2016-03-22
NO2929995T3 (enExample) 2018-02-03
EP3881868C0 (en) 2023-09-27
EP4303232A3 (en) 2024-04-17
AU2021204054B2 (en) 2023-04-20
JP6687712B2 (ja) 2020-04-28
EP3300745B1 (en) 2019-09-11
US20230051989A1 (en) 2023-02-16
KR102813881B1 (ko) 2025-05-28
JP7317159B2 (ja) 2023-07-28
KR20190131152A (ko) 2019-11-25
NZ750521A (en) 2021-03-26
HUE036250T2 (hu) 2018-06-28
ES2758227T3 (es) 2020-05-04
EP2956175B1 (en) 2017-10-04
IL272279B2 (en) 2024-02-01
US12371466B2 (en) 2025-07-29
US10888581B2 (en) 2021-01-12
LT2956175T (lt) 2017-12-11
SI3613439T1 (sl) 2021-11-30
KR20230022452A (ko) 2023-02-15
AU2019246785A1 (en) 2019-10-31
NZ710925A (en) 2021-03-26
US10632152B2 (en) 2020-04-28
DK2956175T3 (da) 2017-11-27
JP7014843B2 (ja) 2022-02-01
AU2019246785B2 (en) 2021-04-08
AU2014216130B2 (en) 2017-11-16
IL272279B1 (en) 2023-10-01
EP4303232A2 (en) 2024-01-10
US10105391B2 (en) 2018-10-23
DK3300745T3 (da) 2019-11-04
IL240472A0 (en) 2015-09-24
CA2901115A1 (en) 2014-08-21
HK1218625A1 (zh) 2017-03-03
PL2956175T3 (pl) 2018-05-30
CN105142677A (zh) 2015-12-09
MX2015010522A (es) 2016-06-23
US9821012B2 (en) 2017-11-21
MX369545B (es) 2019-11-12
JP2023145542A (ja) 2023-10-11
US20250136659A1 (en) 2025-05-01
EP2956175A4 (en) 2016-08-24
JP2019068822A (ja) 2019-05-09
HK1253407A1 (en) 2019-06-14
PT2956175T (pt) 2017-12-26
US20150368342A1 (en) 2015-12-24
EP3300745B9 (en) 2020-04-15
US20170340672A1 (en) 2017-11-30
US12161672B2 (en) 2024-12-10
PL3613439T3 (pl) 2021-11-22
HRP20192123T1 (hr) 2020-02-21
BR112015019640A2 (pt) 2021-08-03
JP6450690B2 (ja) 2019-01-09
AU2018201102A1 (en) 2018-03-08
EP2956175A1 (en) 2015-12-23
EP3300745A1 (en) 2018-04-04
US11478510B2 (en) 2022-10-25
EP3881868B1 (en) 2023-09-27
JP7676476B2 (ja) 2025-05-14
US20200237824A1 (en) 2020-07-30
KR102132246B1 (ko) 2020-07-09
ES2758227T9 (es) 2020-05-12
US20180042963A1 (en) 2018-02-15
US20180085401A1 (en) 2018-03-29
AU2023204612B2 (en) 2025-04-24
IL272279A (en) 2020-02-27
JP2022046809A (ja) 2022-03-23
PT3300745T (pt) 2019-11-27
PL3300745T3 (pl) 2020-03-31
US9587020B2 (en) 2017-03-07
LT3300745T (lt) 2019-12-10
IL240472B (en) 2020-02-27
CY1122386T1 (el) 2021-01-27
HUE047487T2 (hu) 2020-04-28
JP2020121982A (ja) 2020-08-13
CN110423282A (zh) 2019-11-08
AU2021204054A1 (en) 2021-07-08
ES2653487T3 (es) 2018-02-07
KR20210147101A (ko) 2021-12-06
AU2014216130A1 (en) 2015-08-27
EP3881868A1 (en) 2021-09-22
US20160185862A1 (en) 2016-06-30
IL305629A (en) 2023-11-01
CN110423282B (zh) 2023-09-08
KR102064230B1 (ko) 2020-01-13
MX2019013498A (es) 2020-01-20
CN105142677B (zh) 2019-08-30
ES2868247T3 (es) 2021-10-21
US20170143765A1 (en) 2017-05-25
EP3613439A1 (en) 2020-02-26
WO2014127261A1 (en) 2014-08-21
EP3613439B1 (en) 2021-04-07
AU2023204612A1 (en) 2023-08-03
KR20200083682A (ko) 2020-07-08
US20210196757A1 (en) 2021-07-01
KR20150119134A (ko) 2015-10-23
SI3300745T1 (sl) 2020-01-31

Similar Documents

Publication Publication Date Title
PT3613439T (pt) Recetor de antigénio quimérico e métodos de utilização do mesmo
IL281819A (en) Chimeric antigen receptors and methods of making
IL290547A (en) Antibodies and methods of use
IL280155A (en) Anti- SIGLEC-8 antibodies and methods of using them
IL263466A (en) Anti-cd3 antibodies and methods of use
IL254068A0 (en) Anti-dll3 chimeric antigen receptors and methods of use
PT3215532T (pt) Anticorpos anti-tim3 e métodos de utilização
IL244495B (en) Anti-alpha-synuclein antibodies and methods of use
PT3114147T (pt) Recetor de antigénio quimérico
CL2016001519A1 (es) Anticuerpos anti-tau(ps422) humanizados y métodos de utilización
IL244643A0 (en) Anti-ly6e antibodies and methods of use
PT3052525T (pt) Anticorpos anti-epcam e métodos de utilização